Supplemental Online Content

Wang T, Tang J, Yang H, et al. Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the APPROVE randomized clinical trial. *JAMA Oncol*. Published online June 30, 2022. doi:10.1001/jamaoncol.2022.2253

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. List of 11 participating sites.

Site name	Number of recruited patients
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	73
Hunan Cancer Hospital	20
Yunnan Provincial Cancer Center	17
West China Second University Hospital	12
Cancer Hospital of China Medical University	11
Chongqing University Cancer Hospital	8
The First Hospital of Jilin University	5
Xiangya Hospital	2
Guangxi Medical University Affiliated Tumor Hospital	2
The Second Affiliated Hospital of Dalian Medical University	1
Hubei Cancer Hospital	1

eTable 2. Treatment-emergent adverse events

Events, No. (%)	Apatinib plus PLD group (*n* = 74)				PLD group (*n* = 72)			
	All Grades	Grade 1-2	Grade 3	Grade 4	All Grades	Grade 1-2	Grade 3	Grade 4
Any	69 (93.2%)	37 (50.0%)	30 (40.5%)	2 (2.7%)	61 (84.7%)	47 (65.3%)	14 (19.4%)	0 (0%)
WBC decrease	45 (60.8%)	40 (54.1%)	5 (6.8%)	0 (0%)	36 (50.0)	33 (45.8%)	3 (4.2%)	0 (0%)
Neutrophil count decrease	44 (59.5%)	33 (44.6%)	11 (14.9%)	0 (0%)	27 (37.5%)	21 (29.2%)	6 (8.3%)	0 (0%)
Oral ulcer	21 (28.4%)	20 (27.0%)	1 (1.4%)	0 (0%)	9 (12.5%)	7 (9.7%)	2 (2.8%)	0 (0%)
Hand-foot syndrome	19 (25.7%)	15 (20.3%)	3 (4.1%)	1 (1.4%)	2 (2.8%)	0 (0%)	2 (2.8%)	0 (0%)
Anaemia	16 (21.6%)	15 (20.3%)	1 (1.4%)	0 (0%)	16 (22.2%)	13 (18.1%)	3 (4.2%)	0 (0%)
Fatigue	15 (20.3%)	15 (20.3%)	0 (0%)	0 (0%)	8 (11.1%)	8 (11.1%)	0 (0%)	0 (0%)
Nausea	14 (18.9%)	13 (17.6%)	1 (1.4%)	0 (0%)	19 (26.4%)	19 (26.4%)	0 (0%)	0 (0%)
Hypertension	13 (17.6%)	7 (9.5%)	6 (8.1%)	0 (0%)	1 (1.4%)	1 (1.4%)	0 (0%)	0 (0%)
Oral mucositis	12 (16.2%)	10 (13.5%)	1 (1.4%)	1 (1.4%)	6 (8.3%)	6 (8.3%)	0 (0%)	0 (0%)
Platelet count decrease	12 (16.2%)	10 (13.5%)	2 (2.7%)	0 (0%)	3 (4.2%)	3 (4.2%)	0 (0%)	0 (0%)
Vomiting	11 (14.9%)	11 (14.9%)	0 (0%)	0 (0%)	10 (13.9%)	10 (13.9%)	0 (0%)	0 (0%)
AST increase	11 (14.9%)	11 (14.9%)	0 (0%)	0 (0%)	2 (2.8%)	2 (2.8%)	0 (0%)	0 (0%)
Dizziness	11 (14.9%)	10 (13.5%)	1 (1.4%)	0 (0%)	2 (2.8%)	2 (2.8%)	0 (0%)	0 (0%)
Headache	11 (14.9%)	10 (13.5%)	1 (1.4%)	0 (0%)	3 (4.2%)	3 (4.2%)	0 (0%)	0 (0%)
Proteinuria	11 (14.9%)	9 (12.2%)	2 (2.7%)	0 (0%)	2 (2.8%)	2 (2.8%)	0 (0%)	0 (0%)
Urine leucocyte positive	8 (10.8%)	8 (10.8%)	0 (0%)	0 (0%)	2 (2.8%)	2 (2.8%)	0 (0%)	0 (0%)

AST, aspartate aminotransferase; PLD, pegylated liposomal doxorubicin; WBC, white blood cell count. Treatment-emergent adverse events occurring in 10% or more of patients in either group are listed.

eFigure. Subgroup Analyses of Progression-Free Survival.